Use of innovation payments to encourage the adoption of new medical technologies in the English NHS

Published on Sep 1, 2013in Health policy and technology
· DOI :10.1016/J.HLPT.2013.05.001
Corinna Sorenson14
Estimated H-index: 14
(LSE: London School of Economics and Political Science),
Michael Drummond73
Estimated H-index: 73
(Ebor: University of York),
Grahame Wilkinson3
Estimated H-index: 3
(LSE: London School of Economics and Political Science)
Abstract Objectives This study aimed to investigate the use of innovation payments in the English NHS. Methods A structured on-line survey was developed to explore the use of innovation payments. The survey was disseminated to NHS hospital finance managers. A total of 20 surveys ( n =20) were returned. Results The majority (70%) of responding hospitals have applied for innovation payments. In one-third of cases, the payment was for medical devices, followed by drugs (31%), diagnostics (19%), and other technologies (15%). Innovation payments were generally requested because the existing HRG tariff did not reflect the cost of the technology. Processes for determining the payment varied across hospitals, with rates based on supporting evidence of the technology's benefits most common. While a good concept in principle, only about one-third of respondents believed innovation payments were effective in meeting their aims in practice. Conclusions Improvements to the current approach to innovation payments are needed.
  • References (22)
  • Citations (9)
📖 Papers frequently viewed together
1 Citations
14 Citations
6 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Reinhard BusseH-Index: 48
#2Alexander GeisslerH-Index: 14
Last. Wilm QuentinH-Index: 19
view all 13 authors...
Hospitals in most European countries are paid on the basis of diagnosis related groups. Reinhard Busse and colleagues find much variation within and between systems and argue that they could be improved if countries learnt from each other
107 CitationsSource
#1Saptarshi Basu (FDA: Food and Drug Administration)H-Index: 1
#2John C. Hassenplug (FDA: Food and Drug Administration)H-Index: 1
The U.S. process for approving innovative, high-risk medical devices has been criticized for taking longer than the European process. But a review of the data suggests that it takes the same amount of time or less for U.S. patients to gain access to such devices.
43 CitationsSource
#1David Scheller-Kreinsen (Technical University of Berlin)H-Index: 10
#2Wilm Quentin (Technical University of Berlin)H-Index: 19
Last. Reinhard Busse (Technical University of Berlin)H-Index: 48
view all 3 authors...
Objectives: To assess how diagnosis-related group– based (DRG-based) hospital payment systems in 12 European countries participating in the EuroDRG project pay and incorporate technological innovation. Methods: A standardized questionnaire was used to guide comprehensive DRG system descriptions. Researchers from each country reviewed relevant materials to complete the questionnaire and drafted standardized country reports. Two characteristics of DRG-based hospital payment systems were identified...
43 CitationsSource
The current European regulatory framework—CE marking— might provide sufficient safeguards for electric toasters and kettles, but it is not adequate for treatments that can affect symptoms, health related quality of life, serious morbidity, and mortality. There are many kinds of medical devices for myriad purposes in healthcare. All require an adequate regulatory framework to ensure that patients gain clear benefits and are not placed at unreasonable and avoidable risk. The so called class III de...
12 CitationsSource
#1Giulia Cappellaro (Bocconi University)H-Index: 6
#2Simone Ghislandi (Bocconi University)H-Index: 12
Last. Eugenio Anessi-Pessina (UCSC: Catholic University of the Sacred Heart)H-Index: 11
view all 3 authors...
In the last decade the pace of innovation in medical technology has accelerated: hence the need to better identify and understand the real forces behind the adoption and diffusion of medical technology innovations in clinical practice. Among these forces, financial incentives may be expected to play a major role. The purpose of this paper was to assess the influence of financing mechanisms for new medical devices and correlated procedures on their diffusion. The analysis was carried out in the I...
31 CitationsSource
AbstractMost new medical devices in Germany are first introduced in the inpatient sector. The key hurdles to marketing them are thus to ensure their inclusion in the German Diagnosis-Related Group (G-DRG) system and to bridge the financial gap in the interim. In 2005, a system of extrabudgetary payments was introduced to bridge this gap and to expedite the inclusion of new technologies in the G-DRG system. The present study aims (1) to describe prototypical regulatory pathways for including new ...
10 CitationsSource
The producers of medical technology constantly strive to innovate and to improve their products for the benefit of patients. With each new generation of devices enabling less invasive techniques, better clinical outcomes and reduced recovery times, patients are direct beneficiaries of this commitment to innovation. Innovation and patient access to technology are inseparably linked with each national health system's respective coverage, procurement and reimbursement policies. If a particular inno...
20 CitationsSource
Preface Technological Change & Growth of Health Care Spending The Long-Term Outlook for Health Care Spending Index.
45 Citations
#1Jonas Schreyögg (Technical University of Berlin)H-Index: 25
#2Michael Bäumler (Technical University of Berlin)H-Index: 3
Last. Reinhard Busse (Technical University of Berlin)H-Index: 48
view all 3 authors...
Dramatic increases in health expenditures have led to a substantial number of regulatory interventions in the markets for devices over the last years. However, little attention has been paid thus far to the regulation of medical devices and its effects. This article explores the policies pursued by European countries to find the right balance between improving access to new medical devices and restricting market forces to contain costs and ensure affordability. We outline the medical device poli...
50 CitationsSource
#1Alexandra T. Clyde (Medtronic plc)H-Index: 1
#2Lindsay BockstedtH-Index: 1
Last. Christine Jackson (Medtronic plc)H-Index: 1
view all 4 authors...
We describe the new technology add-on payment (NTAP) program used by the Centers for Medicare and Medicaid Services (CMS) to provide additional payment for breakthrough technologies in the Medicare hospital inpatient prospective payment system (IPPS). We also evaluate spending under the program. Our findings suggest that the criteria established by the CMS to limit qualifying technologies, combined with an improvement in overall payment adequacy for the new technologies that qualify for NTAPs, m...
20 CitationsSource
Cited By9
#1Patricia Ex (Technical University of Berlin)H-Index: 1
#2Verena Vogt (Technical University of Berlin)H-Index: 6
Last. Cornelia Henschke (Technical University of Berlin)H-Index: 8
view all 4 authors...
: Most hospital payment systems based on diagnosis-related groups (DRGs) provide payments for newly approved technologies. In Germany, they are negotiated between individual hospitals and health insurances. The aim of our study is to assess the functioning of temporary reimbursement mechanisms. We used multilevel logistic regression to examine factors at the hospital and state levels that are associated with agreeing innovation payments. Dependent variable was whether or not a hospital had succe...
1 CitationsSource
#1Patricia Ex (Technical University of Berlin)H-Index: 1
#2Cornelia Henschke (Technical University of Berlin)H-Index: 8
This paper empirically investigates the impact of additional reimbursement instruments on the diffusion of new technologies in inpatient care. Using 2010–2014 German panel data on hospital level for every patient undergoing coronary angioplasty, this study examines the utilisation of drug-eluting balloon catheters (DEB) over time while additional payment instruments changed. Hypothesising that the utilisation of DEB increased abruptly when a new reimbursement instrument came into force, we estim...
#1Susanne Felgner (Technical University of Berlin)H-Index: 2
#2Patricia Ex (Technical University of Berlin)H-Index: 1
Last. Cornelia Henschke (Technical University of Berlin)H-Index: 8
view all 3 authors...
Abstract Objectives To foster value-based pricing and coverage with evidence development in Germany, certain new diagnostic and treatment methods have been subject to a benefit assessment since 2016 to determine their reimbursement. Although this is a paradigm shift, the German approach is limited to some few specific technologies for which reimbursement is requested. As physicians encounter this regulatory instrument, the aim of the study was to understand physicians' decision making regarding ...
1 CitationsSource
#1Iakovos Theodoulou (Guy's Hospital)H-Index: 1
#2Akshaya Mohan Reddy (University of Leicester)H-Index: 1
Last. Jeremy Wong (Guy's Hospital)H-Index: 1
view all 3 authors...
Background Workforce planning in the British healthcare system (NHS) is associated with significant costs of agency staff employment. The introduction of a novel software (ABG) as a ‘people to people economy’ (P2PE) platform for temporary staff recruitment offers a potential solution to this problem. Consequently, the focus of this study was twofold – primarily to explore the locum doctor landscape, and secondarily to evaluate the implementation of P2PE in the healthcare industry.
2 CitationsSource
#1Cornelia Henschke (Technical University of Berlin)H-Index: 8
#2Dimitra Panteli (Technical University of Berlin)H-Index: 13
Last. Reinhard Busse (Technical University of Berlin)H-Index: 48
view all 4 authors...
Objectives: The suitability of general HTA methodology for medical devices is gaining interest as a topic of scientific discourse. Given the broad range of medical devices, there might be differences between groups of devices that impact both the necessity and the methods of their assessment. Our aim is to develop a taxonomy that provides researchers and policy makers with an orientation tool on how to approach the assessment of different types of medical devices. Methods: Several classification...
9 CitationsSource
This paper examines the incentive to adopt a new technology resulting from common payment systems, namely mixed cost reimbursement and DRG reimbursement. Adoption is based on a cost–benefit criterion. We find that retrospective payment systems require a large enough patient benefit to yield adoption, while under DRG-linked payment, adoption may arise in the absence of patients benefits when the differential reimbursement for the old vs new technology is large enough. Also, mixed cost reimburseme...
1 CitationsSource
#1Jennifer SurteesH-Index: 1
#2Louise KnightH-Index: 20
Last. Helen ShiptonH-Index: 16
view all 3 authors...
Healthcare providers are under ever increasing pressure to deliver more technologically advanced care without increasing costs. Innovation is essential (Darzi, 2008), and for this healthcare providers rely on innovation within commercial companies. SMEs have an important part to play in this sector (NHS Supply Chain Parliamentary Brief, 2013). Collaboration between SME suppliers and the NHS for innovation forms the focus of this paper. We examine the academic literature on interorganizational in...
Nov 1, 2014 in BIBM (Bioinformatics and Biomedicine)
#1Mark Beattie (Ulster University)H-Index: 3
#2Huiru Zheng (Ulster University)H-Index: 25
Last. Paul McCullagh (Ulster University)H-Index: 21
view all 4 authors...
A dramatic shift in population ageing is taking place, which is subsequently leading to a rise in the prevalence of chronic conditions. COPD is one such condition that places a heavy burned on national Health Services. A healthier lifestyle can greatly reduce the speed of conditional decline in those with COPD and therefore provide a better quality of life. This paper investigates how technology can be utilized for lifestyle support through self-management providing participants with the ability...
3 CitationsSource
#1Wendy L. CurrieH-Index: 1
The challenge to provide a nation-wide integrated health service is central to UK government policy. The National Program for Information Technology was launched in 2002 to transform healthcare using information and communications technology. As the largest, non-military, non-scientific government funded IT program worldwide, it was planned over a decade with an estimated total cost expected to exceed £20bn. This paper is a longitudi - nal study of the National Care Record Service, which was the...
2 Citations